Nasdaq Aura News Today

Aura Biosciences (NASDAQ:AURA – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Institutional and Insider Ownership 96.8% of Aura […]

Levin Capital Strategies L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) by 15.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 81,095 shares of the company’s stock after acquiring an additional 11,095 shares during the period. Levin Capital Strategies L.P. owned […]

Aura Biosciences (NASDAQ:AURA – Free Report) had its price target reduced by BTIG Research from $38.00 to $21.00 in a research report released on Friday, Benzinga reports. BTIG Research currently has a buy rating on the stock. Separately, JMP Securities lowered their target price on shares of Aura Biosciences from $21.00 to $19.00 and set […]

Regency Capital Management Inc. DE reduced its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) by 1.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 543,675 shares of the company’s stock after selling 10,611 shares during the period. […]

Aura Biosciences (NASDAQ:AURA – Get Rating) had its price target decreased by JMP Securities from $25.00 to $24.00 in a research report released on Friday, The Fly reports. Aura Biosciences Trading Up 0.4 % AURA stock opened at $10.25 on Friday. Aura Biosciences has a twelve month low of $8.13 and a twelve month high […]

Monashee Investment Management LLC purchased a new stake in Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 131,640 shares of the company’s stock, valued at approximately $1,382,000. Monashee Investment Management LLC owned approximately […]

Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,560,000 shares, an increase of 24.8% from the March 15th total of 1,250,000 shares. Approximately 6.0% of the company’s stock are sold short. Based […]

Aura Biosciences (NASDAQ:AURA – Get Rating) and Scholar Rock (NASDAQ:SRRK – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation. Profitability This table compares Aura Biosciences and Scholar Rock’s […]

Aura Biosciences (NASDAQ:AURA – Get Rating) is one of 283 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Aura Biosciences to similar companies based on the strength of its dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership. Analyst Recommendations This is […]

Aura Biosciences (NASDAQ:AURA – Get Rating) is one of 282 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Aura Biosciences to related businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership. Analyst Ratings This is […]